Meeting
2024 ASCO Genitourinary Cancers Symposium
AI-based morphologic model for prediction of individual patient response to immune checkpoint inhibitors for bladder cancer.
Authors
Monica Nair
Cleveland Clinic Lerner College of Medicine, Cleveland, OH
Monica Nair , Ross Liao , Parag Jain , Chensu Xie , Hassan Muhammad , Wei Huang , Hirak S Basu , George Wilding , Rajat Roy , C. Marcela Diaz-Montero , Tae Hyun Hwang , Scott Dawsey , Jane Nguyen , Eric A. Klein , Shilpa Gupta , Omar Y. Mian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 686)
DOI
10.1200/JCO.2024.42.4_suppl.686
Abstract #
686
Poster Bd #
L8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Improved overall survival of metastatic cancers in the United States across all age groups in the immunotherapy era: Implications for considering elderly patients (age ≥ 75) for immune checkpoint inhibitors (ICIs).
First Author: Yu-Wei Chen
Poster
2022 ASCO Annual Meeting
Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy.
First Author: Ryan Yong Kiat Tay
Poster
2022 ASCO Genitourinary Cancers Symposium
Genomic sequencing for bladder urothelial carcinoma and its clinical implications for immunotherapy.
First Author: Ryul Kim
Poster
2021 ASCO Annual Meeting
Association with immune checkpoint inhibitor efficacy of a 27-gene classifier in renal cell cancer.
First Author: Robert Seitz